Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is experiencing promising growth in its US demand and market access, as evidenced by strong sales and a growing number of authorized treatment centers. Additionally, the company's T cell programming technologies show potential for expanding its therapeutic offerings and addressing previously challenging diseases. Furthermore, recent positive real-world evidence and swift UK launch suggest a strong and swift pace for market adoption, with potential for near-term changes to NCCN guidelines. These factors, along with a solid revenue guidance and promising revenue forecasts, point to a positive and potentially strong future for Autolus Therapeutics' stock.

Bears say

Autolus Therapeutics is facing a potential long-term obstacle with the expected data readouts for its various clinical trials not being until 2026 and 2027 and the company potentially expending significant resources and time to expand the label for its flagship product, Aucatzyl, into the pediatric ALL market. Further complicating matters, the company faces intense competition from established players in the CAR-T therapy market and a highly saturated market for multiple myeloma treatments. Additionally, there remains plenty of room for growth in the pediatric r/r ALL market, which could further delay any potential revenue growth.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.